U.S. approval of Merck cancer immunotherapy expected soon

U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

Read Full Article

AstraZeneca strikes deal with biotech firm Immunocore to develop cancer drug

AstraZeneca's MedImmune unit has partnered with Immunocore, a private British biotechnology company, to develop a cancer drug that would tap on the body's immune system, Reuters reported.

Read Full Article

ImmunGene Inc raises USD9 million in Series A round

USD9 million was raised in Series A funding round for ImmunGene Inc.

Read Full Article

immatics biotechnologies closes Series D funding round

immatics raises EUR34 million in its latest Series D round financing.

Read Full Article
1 2

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics